ES2069987T3 - Composicion farmaceutica de biodisponibilidad potenciada que contiene probucol. - Google Patents

Composicion farmaceutica de biodisponibilidad potenciada que contiene probucol.

Info

Publication number
ES2069987T3
ES2069987T3 ES92900932T ES92900932T ES2069987T3 ES 2069987 T3 ES2069987 T3 ES 2069987T3 ES 92900932 T ES92900932 T ES 92900932T ES 92900932 T ES92900932 T ES 92900932T ES 2069987 T3 ES2069987 T3 ES 2069987T3
Authority
ES
Spain
Prior art keywords
pharmaceutical
probucol
availability
composition containing
bio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900932T
Other languages
English (en)
Inventor
Kenneth G Bassler
Phadke S Deepak
Melissa P Neddermeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2069987T3 publication Critical patent/ES2069987T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA DE PROBUCOL QUE AUMENTA LA BIODISPONIBILIDAD DEL MEDICAMENTO Y REDUCE LA VARIABILIDAD DEL NIVEL DE MEDICAMENTO EN EL PLASMA EN UNA POBLACION DE PACIENTES, COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE PROBUCOL DISUELTO EN UN ESTER DE GLICOL PROPILENO DE ACIDOS GRASOS, EN DONDE LOS ACIDOS GRASOS ESTAN SELECCIONADOS DEL GRUPO COMPUESTO DE ACIDOS GRASOS REPRESENTADOS POR CXH2XO2, EN DONDE X ES 4,6,8,10,12,14,16.
ES92900932T 1990-12-18 1991-11-15 Composicion farmaceutica de biodisponibilidad potenciada que contiene probucol. Expired - Lifetime ES2069987T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62954090A 1990-12-18 1990-12-18

Publications (1)

Publication Number Publication Date
ES2069987T3 true ES2069987T3 (es) 1995-05-16

Family

ID=24523438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900932T Expired - Lifetime ES2069987T3 (es) 1990-12-18 1991-11-15 Composicion farmaceutica de biodisponibilidad potenciada que contiene probucol.

Country Status (17)

Country Link
EP (1) EP0563112B1 (es)
JP (1) JP3127998B2 (es)
KR (1) KR0177845B1 (es)
AT (1) ATE117200T1 (es)
AU (1) AU647563B2 (es)
CA (1) CA2097827C (es)
DE (1) DE69106892T2 (es)
DK (1) DK0563112T3 (es)
ES (1) ES2069987T3 (es)
FI (1) FI102457B1 (es)
GR (1) GR3015837T3 (es)
HU (1) HU210565B (es)
IE (1) IE65578B1 (es)
IL (1) IL100390A (es)
NO (1) NO303526B1 (es)
NZ (1) NZ240961A (es)
WO (1) WO1992010996A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031979A1 (en) * 1994-05-19 1995-11-30 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
JP2002532539A (ja) * 1998-12-18 2002-10-02 アボット・ラボラトリーズ 脂質調節剤を含む新規な製剤
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
AU2571400A (en) * 1999-02-23 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Seam soft capsule preparations containing dihydrobenzofuran derivative
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
WO2005037251A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
KR20210053877A (ko) 2018-06-26 2021-05-12 리보노바 인크. 미토콘드리아 기능장애를 치료하는 방법
US12016830B2 (en) * 2022-07-01 2024-06-25 Acrotech Biopharma, LLC Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
CN116617179B (zh) * 2023-05-19 2024-03-29 齐鲁制药有限公司 一种普罗布考软胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862332A (en) * 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US4902513A (en) * 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament

Also Published As

Publication number Publication date
CA2097827A1 (en) 1992-06-19
KR930702965A (ko) 1993-11-29
DK0563112T3 (da) 1995-04-10
HU9301769D0 (en) 1993-09-28
NO303526B1 (no) 1998-07-27
FI102457B (fi) 1998-12-15
EP0563112A1 (en) 1993-10-06
IE65578B1 (en) 1995-11-01
NZ240961A (en) 1994-03-25
JP3127998B2 (ja) 2001-01-29
IE914401A1 (en) 1992-07-01
ATE117200T1 (de) 1995-02-15
EP0563112B1 (en) 1995-01-18
NO932236L (no) 1993-06-17
JPH06503340A (ja) 1994-04-14
AU647563B2 (en) 1994-03-24
DE69106892T2 (de) 1995-05-18
FI932769A0 (fi) 1993-06-16
FI102457B1 (fi) 1998-12-15
IL100390A0 (en) 1992-09-06
HU210565B (en) 1995-05-29
KR0177845B1 (ko) 1999-03-20
GR3015837T3 (en) 1995-07-31
FI932769L (fi) 1993-06-16
HUT64218A (en) 1993-12-28
AU9067891A (en) 1992-07-22
CA2097827C (en) 2002-07-23
IL100390A (en) 1996-12-05
WO1992010996A1 (en) 1992-07-09
NO932236D0 (no) 1993-06-17
DE69106892D1 (de) 1995-03-02

Similar Documents

Publication Publication Date Title
ES2195175T3 (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
ES2069987T3 (es) Composicion farmaceutica de biodisponibilidad potenciada que contiene probucol.
MX9203150A (es) Nuevos esteres de acidos tienilcarboxilicos de aminoalcoholes, sus productos de cuaternizacion y las composiciones farmaceuticas que los contienen.
BR9509550A (pt) Formulações de ciclosporina para administração oral com composição simples e alta biodisponibilidade e processo para sua produção
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
ES2174814T3 (es) Acidos grasos esenciales destinados en la prevencion de accidentes cardio-vasculares.
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
NO940277L (no) Triglycerider og blandinger av slike
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
CY1112333T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα
ES2033259T3 (es) Bases de liberacion controlada de productos farmaceuticos.
ES2056852T3 (es) Un procedimiento para la extraccion del ester etilico del acido docosahexenoico a partir de aceites de pescado y composiciones farmaceuticas y/o dieteticas que contienen una mezcla de esteres etilicos del acido docosahexenoico y eicosapentenoico.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
DE69319440D1 (de) Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2054333T3 (es) Forma de dosificacion para administrar un antagonista del calcio.
ES2179304T3 (es) Esteres de polietilenglicol de acidos grasos poliinsaturados.
KR930012009A (ko) 동맥의 재폐색 방지법
IT1204571B (it) Esteri di 1,4:3,6-dianidrosorbitolo-2-mononitrato e 5-mononitrato,loro procedimento di preparazione e loro composizioni farmaceutiche
ES2142825T3 (es) Uso de 1(rs)-(1-trifluoroacetil-2-metilpropil)amida de 4-(4-clorofenil-sulfonilcarbamoil)benzoil-l-valil-l-prolina para la preparacion de un medicamento para el tratamiento de enfermedades vasculares.
GT198900080A (es) Procedimiento de preparar una composicion farmaceutica a base de trimebutina
Wenderoth Aspects of the new eicosanoid-research.).

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 563112

Country of ref document: ES